Analyst consensus rating
Biodexa Pharmaceuticals Analyst Rating: none
Direct answer
Biodexa Pharmaceuticals's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.97.
Forecast evidence checked October 18, 2026.
Get free Biodexa Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.46
- Average price target
- $8.97
- High price target
- $8.97
- Low price target
- $8.97
- Low target gap
- +1,867.7%
- Target upside
- +1,867.7%
- High target gap
- +1,867.7%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Biodexa Pharmaceuticals?
Biodexa Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $8.97.
How far are Biodexa Pharmaceuticals's low and high targets from the recorded price?
The low target implies +1,867.7%, while the high target implies +1,867.7%.
How many analysts are included in Biodexa Pharmaceuticals's consensus?
The verified consensus includes 1 analysts.
How is Biodexa Pharmaceuticals's target upside or downside calculated?
The average target of $8.97 is divided by the recorded price of $0.46, then one is subtracted to produce +1,867.7%. This does not guarantee a future return.
When was Biodexa Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.